General Information


We are a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Our pipeline is based on our platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. 

Employees: 30
Founded: 2011
Contact Information
Address 180 Kimball Way, Suite 200, South San Francisco, CA 94080, US
Phone Number (650) 822-5500
Web Address
View Prospectus: Annexon
Financial Information
Market Cap $612.1mil
Revenues $0.15 mil (last 12 months)
Net Income $-41.98 mil (last 12 months)
IPO Profile
Symbol ANNX
Exchange NASDAQ
Shares (millions): 14.8
Price range $17.00 - $17.00
Est. $ Volume $250.8 mil
Manager / Joint Managers J.P. Morgan/ BofA Securities/ Cowen
CO-Managers -
Expected To Trade: 7/24/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change